1. Reemtsma K. Xenografts. Transpl Proc 1989; 21 (1): 517-519.
2. Najarian JS. Overview of in vivo xenotransplantation studies: Prospects for the future. Transpl Proc 1992; 24(2): 733-738.
3. Edwards J. Complement activation by xenogeneic red blood cells. Transplantation 1981; 31: 226-27.
4. Alcxandre GPJ, Squifflet JP, De Bruyere M. et al. Pre¬sent experiences in a series of 26 ABO-incompalible li¬ving donor renal allografts. Transplant Proc 1987; 19: 4538-4542.
5. Bannett AD, Me Alack RF, Raja R et al. Experiences with known ABO-mismatched renal transplants. Trans¬plant Proc 1987; 19: 4543-4546.
6. Palmer A, Welsh K, Gjorstrup P, et al. Removal of anti-HLA antibodies by extracorporeal immunoadsorption to enable renal transplantation. Lancet 1989; 1: 10-12.
7. Platt JL, Vercellotti GM, Dalmasso AP, et al. Transplan¬tation of discordant xenografts: A review of progress. Immunol Today 1990; 11: 450-456. ,
8. Platt JL, Dalmasso AP, Vercellotti GM, Lindman BJ,
Turman MA, Bach FH. Endothelial cell proteoglycans in xenotransplantation. Transplant Proc 1990; 22 (3): 1066.
9. Platt JL, Bach FH. The barrier to xenotransplantation.
Transplantation 1991; 52: 937-947.
10. Hammer C. Xenotransplantation: State of art. Transplant
Proc 1993; 25 (4), suppl 3 : 35-37.
11. Bach FH. Discordant Xenografting: A summary and look
to the future. Transplant Proc 1992; 24(2): 739-742.
12. Invcrardi LA, Bender JR, Samaja M, Pardi R. The role of NK cells in the recognition of xenografts. Transplant
Proc 1992; 24:459-461.
13. Platt JL. Xenotransplantation: Immunological hurdles and prospects for future success. J Nephrol 1993; 6(4): 182-192.
14. Casali P, Notkins AL. CD5+B lymphocytes, polyreactive antibodies and the human B-cell repertoire. Immunol To¬day 1989; 10: 364-368.
15. Bcndtzen K, Sevenson M, Jonsson V, Hippe E. Autoanti-bodies to cytokines-friends or foes. Immunol Today 1990; 11: 167-169.
16. Avrameas S. Natural antibodies 1991; 12: 154-159.
17. Hammer C. Preformed natural antibodies (PNAB) and possibilities of modulation of hyperacute xenogeneic re¬jection. Transplant Proc 1989; 21: 522-523.
18. He X Tepper I, Copet L, Smith C, Rccmtsma K, Rose E. Incidence of preformed antibodies against potential xe-nodonors in human sera. Transplantation 1990; 49: 1022¬1024.
19. Platt JL, Fischel RJ, Matas AJ, Reif SA, Bolman RM, Bach FH. Immunopathology of hyperacute xenograft re¬jection in a swine-to-primate model. Transplantation
1991;52:214-220.
20. Platt JL, Lindman BJ, Chen H, Spitalnik SL, Bach FH.
Endothelial cell antigens recognized by xenoreactive hu¬man natural antibodies. Transplantation 1990; 50: 817¬822.
21. Geller RL, Bach FH, Vercellotti GM, Fischel RJ, Bol-man RM, Platt JL. Activation of endothelial cells in hyperacul xenograft rejection. Transplant Proc 1992; 24:
592.
22. Stevens RB, Platt JL. The pathogenesis of hyperacute xe-
nograft rejection. Am J Kidney Dis 1992; 220 (4) 414¬421.
23. Abbas AK, Lichtman AH, Pober JS. Cellular and Mole¬cular Immunology, WB Saunders, Philadelphia, 1991, pp 269-275.
24. Inverardi L, Samaja M, Molterlini R, et al. Early recogni¬tion for a discordant xenogeneik organ by human circula¬ting lymphocytes. J Immunol 1992; 149: 1416-1423.
25. Platt JL, VercoHotti GM, Dalmasso AP et al. Transplan¬tation of discordant xenografts: a review of progress. Im¬munol Today 1990; 11: 450-456.
11
26. Auchincloss H Jr. Xenogeneic transplantation. Transplantation 1988; 46: 1-20.
27. Turman CA, Casali P, Notkins AL, Bach FH, Platt JL. Polyreactivity and antigen specificty of human xenorcac-tive monoclonal and serum natural antibodies. Trans¬plantation 1991; 52: 710-717.
28. Figueroa J, Fuad S, Kunjummen BD, Platt JL, Bach FH. Suppresion of synthesis of natural antibodies by RS-61443: potential use in discordant xenografting. Transplantation 1993; 55: 1371-1374.
29. Geller RL, Bach FH, Turman MA, Casali P, Platt JL.
Evidence that polyreactive antibodies are deposited in re¬jected discordant xenografts. Transplantation 1993; 55: 168-172.
30. Gewurz H, Clark DS, Cooper MD, Varco RL, Good RA. Effect of cobra venom-induced inhibition of complement activity on allograft and xenograft rejection reactions.
Transplantation 1967; 5: 1296-1303.
31. Leventhal JR, Dalmasso AP, Cromwell JW, et al. Prolon¬gation of cardiac xenograft survival by depletion of complement. Transplantation 1993; 56: 1-8.
32. Pruitt SK, Baldwin WM, Marsh HC, et al. The effect of
soluble complement receptor type I on hyperacute xe-nograft rejection. Transplantation 1991; 52: 868-873.
33. Dalmasso AP, Vercollotti GM, Platt JL, Bach FH. Inhibi¬tion of complement-mediated endothelial cell cytotoxi-city by decay accelerating factor: potential for prevention of xenograft hyperacute rejection. Transplantation 1991;
52: 530-533.
34. Akami T, Sawada R, Minato N, et al. Cytoprotective ef¬fect of CD59 antigen on xenotransplantation immunity.
Transplant Proc 1992; 24: 485-487.
35. Cary N, Moody J, Yannoutsos N, Wallwork J, White D.
Tissue expression of human decay accelerating factor, a regulator of complement activation expressed in mice: a potential approach to inhibition of hyperacute xenograft rejection. Transplant Proc 1993; 25: 400-401.
Thank you for copying data from http://www.arastirmax.com